ARQT NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Arcutis Biotherapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 26.86 USD
-1.8% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is 8.9% above the Trend Line and sits at 72.8% of its 52-week range. The latest completed week returned -1.8%, after a 4.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers. Options positioning is volatility with 50/100 conviction, while the latest news-sentiment score is 56/100. Near-term considerations: volume confirmation is below normal; earnings are due in 2d.

Setup score 54 out of 100
Latest Close 26.86 USD 31 Jul 2026
1W Return -1.8% latest completed week
4W Return 4.1% short-term follow-through
12W Return 26.9% quarterly tape
Trend Breadth 61.5% 32 of 52 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • 1 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -1.8% Latest completed week; four-week move 4.1%. Indicator stack 34/64 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 50/100 conviction; expected move 13.4%. News sentiment 56/100 60 relevant articles in the latest sentiment read. Event risk 2d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 8.9% above the Trend Line and sits at 72.8% of its 52-week range. The latest completed week returned -1.8%, after a 4.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5512-week average 0.27

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership5/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.55Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers11 reversal markers

No recent accumulation markers. 1 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 4.1% over four weeks, 26.9% over 12 weeks, and 88.0% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-1.8%
4W4.1%
12W26.9%
26W5.9%
52W88.0%
Active trend streak0 weeks
Active weeks in one year32
Trend breadth61.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.77Latest activity-pressure read.
Pressure change-2.6%Four-week change in activity pressure.
Leadership3.74Latest relative-leadership reading.
RS change438.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 02 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 91% Model confidence 86%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength14/100Blend of value, momentum, and quality. Underlying universe rank 87; rank 1 is best.
Value2/100Relative valuation strength. Underlying universe rank 99; rank 1 is best.
Quality26/100Profitability and accounting quality. Underlying universe rank 75; rank 1 is best.
Momentum95/100Medium-term price momentum. Underlying universe rank 6; rank 1 is best.
Growth89/100Revenue and earnings growth. Underlying universe rank 12; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
8.1x
Market value relative to trailing revenue.
EV / EBITDA
228.9x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
0.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
90.9%
Gross profit retained from each unit of revenue.
Operating margin
2.9%
Operating profit retained from revenue.
Free-cash-flow margin
6.5%
Free cash flow generated from revenue.
Return on invested capital
3.4%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
95.3%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
5.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

ARQT shows volatility options pressure with a 50/100 conviction score, put-call volume ratio of 0.08, expected move of 13.4%, and Sharemaestro trend signal inactive.

Conviction50/100
Expected move13.4%
Put/call volume0.08
Pressure97
Speculation8
Volatility77
Trend agreement0
Open options detail
Insider activity10 / 10

10 acquisitions and 10 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment56/100

Weighted news tone is neutral across 60 relevant articles.

21 positive · 36 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings2dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move13.4%Nearest-chain priced movement where available.
52-week drawdown-15.5%Distance below the 52-week high.
13-week volatility6.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+14.8%Week of 12 Jun.
Worst week-11.0%Week of 6 Mar.
Latest week-1.8%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains7
Flat weeks0
Modest losses5
Sharp losses8
Recent vol6.0%13-week weekly-return volatility.
Base vol7.1%52-week weekly-return volatility.
Up/down split30/22Count of positive and negative weeks in the 52-week window.
Average skew5.8% / -4.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape50/100

Trend, activity pressure, participation, and risk combine to a 50/100 tape read.

 Indicator analysis35/100

Latest 12-week confirmation: trend 0/12, activity pressure 6/12, relative leadership 5/12.

Activity pressure 0.55; 1 reversal markers Factors31/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 55; Small Cap Core rank 98 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options35/100

ARQT shows volatility options pressure with a 50/100 conviction score, put-call volume ratio of 0.08, expected move of 13.4%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 13.4% Sentiment56/100

Weighted news tone is neutral across 60 relevant articles.

Arcutis Biotherapeutics (ARQT) Stock Trades At A Discount To Sales But Fair Value Looks Tight Insiders10 / 10

10 acquisitions and 10 disposals in the latest 180-day insider tape.

 Earnings2d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202626.86 USD-1.8%24.67 USD14.43 USD0.773.746.1MOff
24 Jul 202627.35 USD-4.0%24.75 USD14.32 USD0.786.935.3MOff
17 Jul 202628.49 USD2.7%24.80 USD14.21 USD0.9510.386.7MOff
10 Jul 202627.74 USD7.5%24.78 USD14.10 USD0.973.808.8MOff
3 Jul 202625.81 USD-4.4%24.83 USD13.98 USD0.79-1.104.9MOff
26 Jun 202627.00 USD3.0%25.01 USD13.88 USD0.404.9710.9MOff
19 Jun 202626.21 USD7.5%25.13 USD13.76 USD-0.13-2.0110.4MOff
12 Jun 202624.38 USD14.8%25.24 USD13.65 USD-0.60-5.968.4MOff
5 Jun 202621.23 USD-1.1%25.26 USD13.56 USD-0.88-15.857.4MOff
29 May 202621.46 USD2.9%25.36 USD13.48 USD-0.82-18.646.7MOff
22 May 202620.86 USD-2.2%25.49 USD13.40 USD-0.80-18.4610.7MOff
15 May 202621.32 USD0.7%25.46 USD13.32 USD-0.83-15.5812.8MOff
8 May 202621.17 USD-9.3%25.45 USD13.24 USD-0.84-16.3213.0MOff
1 May 202623.35 USD0.4%25.41 USD13.17 USD-0.93-2.525.4MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.